Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 18;15(9):1549-1553.
doi: 10.18240/ijo.2022.09.20. eCollection 2022.

Efficacy and safety of intravitreal HLX04-O, an anti-VEGF monoclonal antibody, for the treatment of wet age-related macular degeneration

Zhen Zhang  1 , Ying Wu  2 , Ya-Li Lyu  3 , Meng-Qi Chang  4 , Qiu-Jin Xu  4 , Yi-Ming Liu  3 , Wen-Ying Kang  3 , Qing-Yu Wang  3 , Chuan-Ling Li  4
Affiliations

Efficacy and safety of intravitreal HLX04-O, an anti-VEGF monoclonal antibody, for the treatment of wet age-related macular degeneration

Zhen Zhang et al. Int J Ophthalmol. .

Abstract

Aim: To evaluate the efficacy and safety of HLX04-O, an investigational ophthalmic formulation of HLX04 (bevacizumab biosimilar) for intravitreal injection, as a treatment for wet age-related macular degeneration (wAMD) in a phase 1/2 clinical trial (NCT04993352).

Methods: Eligible patients with wAMD were enrolled to receive HLX04-O intravitreal injections at a dose of 1.25 mg/0.05 mL every four weeks. Efficacy and adverse events were evaluated every month during study visits.

Results: A 76-year-old male with wAMD in his left eye participated in the trial and completed six cycles of HLX04-O intravitreal injections. Changes were observed in macular center point thickness (baseline vs last study visit, 437 vs 255 µm) and best-corrected visual acuity letter score (baseline vs last study visit, 36 vs 77) of the affected eye, which indicated an improvement in wAMD over treatment. No adverse events were reported by the data cutoff date.

Conclusion: HLX04-O at 1.25 mg/0.05 mL every four weeks is well tolerated in this patient, demonstrating promising safety and efficacy in wAMD treatment. Large-scale studies are required to confirm the outcomes.

Keywords: HLX04; HLX04-O; anti-vascular endothelial growth factor; bevacizumab; wet age-related macular degeneration.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Optical coherence tomography images of the affected eye during treatment with intravitreal HLX04-O injections
Yellow arrows indicate subretinal fluid. Numbers and line segments (in red) indicate macular center point thickness.
Figure 2
Figure 2. Changes during treatment with intravitreal HLX04-O injections
A: Macular center point thickness; B: BCVA letter score. BCVA: Best-corrected visual acuity; ETDRS: Early Treatment Diabetic Retinopathy Study.
See this image and copyright information in PMC

References

    1. Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147–1159. - PubMed
    1. Wong WL, Su XY, Li X, Cheung CMG, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e116. - PubMed
    1. de Jong EK, Geerlings MJ, den Hollander AI. Genetics and Genomics of Eye Disease. Amsterdam: Elsevier; 2020. Age-related macular degeneration; pp. 155–180.
    1. Khan P, Khan L, Mondal P. Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial. Indian J Ophthalmol. 2016;64(9):694–696. - PMC - PubMed
    1. Henlius' 4th Biologics: Bevacizumab Biosimilar Han-Bei-Tai® Approved by National Medical Products Administration. [Accessed on December 3, 2021]. https://www.henlius.com/en/NewsDetails-3329-26.html.

Associated data

LinkOut - more resources